孟鲁司特治疗支气管哮喘的临床研究(1)
摘 要：目的 分析孟鲁司特对支气管哮喘患者的治疗效果及影响，为临床提供参考。方法 选取2016年1月～2017年1月我院收治的90例支气管哮喘患者，以随机数表法分成观察组与对照组，各45例。对照组予以常规治疗，观察组在常规治疗基础上加用孟鲁司特钠治疗，对比观察两组患者治疗总有效率、临床症状评分及不良反应情况。结果 观察组患者临床治疗总有效率94.33%，高于对照组77.78%，差异有统计学意义(P<0.05)；观察组临床症状评分(0.71±0.23)分，低于对照组(1.67±0.26)分，差异有统计学意义(P<0.05)。观察组不良反应率4.40%与对照组6.60%对比，差异无统计学意义(P>0.05)。结论 孟鲁司特对支气管哮喘患者的治疗效果显著，与常规治疗相比，其不仅可有效提高临床疗效，而且可有效减少不良反应发生率，值得临床推广。
关键词：支气管哮喘；孟鲁司特；临床症状评分
中图分类号：R562.2+5 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.10.047
, 百拇医药
文章编号：1006-1959(2018)10-0140-03
Clinical Study of Montelukast in the Treatment of Bronchial Asthma
LIU Yu-zhen
(Department of Pharmacy，Tianjin Ninghe District Hospital，Tianjin 301500，China)
Abstract：Objective To analyze the treatment effect and influence of montelukast on bronchial asthma patients and provide reference for clinical practice.Methods A total of 90 patients with bronchial asthma admitted to our hospital from January 2016 to January 2017 were randomly divided into observation group and control group，45 cases each.The control group was given routine treatment. The observation group was treated with montelukast sodium on the basis of conventional treatment.The total treatment efficacy，clinical symptom scores，and adverse reactions were compared between the two groups.Results The total effective rate of clinical treatment in observation group was 94.33%，which was higher than 77.78% in control group，the difference was statistically significant(P<0.05)；the clinical symptom score of the observation group(0.71±0.23)was lower than that of the control group(1.67±0.26)，and the difference was statistically significant(P<0.05).The adverse reaction rate in the observation group was 4.40% compared with 6.60% in the control group，with no statistically significant difference(P>0.05).Conclusion Montelukast has a significant therapeutic effect on bronchial asthma patients.Compared with conventional treatment，montelukast can not only effectively improve clinical efficacy，but also can effectively reduce the incidence of adverse reactions and is worthy of clinical promotion.
, 百拇医药
Key words：Bronchial asthma；Montelukast；Clinical symptom score
支气管哮喘(asthma)是慢性炎症性呼吸科疾病，临床表现为喘息、胸闷、咳嗽及呼吸困难等，常发作于夜间与清晨，不仅严重影响患者健康，而且若治疗不及时还可造成患者死亡[1]。临床研究显示，支气管哮喘与患者免疫功能紊乱有直接关系，为此临床上常采用白三烯抑制类药物对其进行治疗，进而有效抑制气道炎症反应，调节免疫功能，改善临床症状[2]。本次我院将孟鲁司特这一新型白三烯受体拮抗剂应用到支气管哮喘临床治疗中，并取得较好临床疗效，现详述如下。
1 资料与方法
1.1 一般资料 选取天津市宁河区医院2016年1月～2017年1月收治的90例支气管哮喘患者，本次研究经过医院伦理委员会批准。依据中华医学会呼吸病学分会哮喘学组制定的《支气管哮喘防治指南(2016年版)》的诊断标准，所有患者均被确诊为支气管哮喘，并排除感染性疾病及近期应用免疫抑制剂或白三烯受体拮抗剂的患者，所有患者均签署知情同意书。以随机数表法将90例患者平均分成观察组与对照组各45例。观察组男性23例，女性22例；年龄14～75岁，平均年龄(33.01±8.14)歲。对照组男性24例，女性21例；年龄15～74岁，平均年龄(33.30±8.32)岁。两组患者一般资料对比，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(刘玉振)
关键词：支气管哮喘；孟鲁司特；临床症状评分
中图分类号：R562.2+5 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.10.047
, 百拇医药
文章编号：1006-1959(2018)10-0140-03
Clinical Study of Montelukast in the Treatment of Bronchial Asthma
LIU Yu-zhen
(Department of Pharmacy，Tianjin Ninghe District Hospital，Tianjin 301500，China)
Abstract：Objective To analyze the treatment effect and influence of montelukast on bronchial asthma patients and provide reference for clinical practice.Methods A total of 90 patients with bronchial asthma admitted to our hospital from January 2016 to January 2017 were randomly divided into observation group and control group，45 cases each.The control group was given routine treatment. The observation group was treated with montelukast sodium on the basis of conventional treatment.The total treatment efficacy，clinical symptom scores，and adverse reactions were compared between the two groups.Results The total effective rate of clinical treatment in observation group was 94.33%，which was higher than 77.78% in control group，the difference was statistically significant(P<0.05)；the clinical symptom score of the observation group(0.71±0.23)was lower than that of the control group(1.67±0.26)，and the difference was statistically significant(P<0.05).The adverse reaction rate in the observation group was 4.40% compared with 6.60% in the control group，with no statistically significant difference(P>0.05).Conclusion Montelukast has a significant therapeutic effect on bronchial asthma patients.Compared with conventional treatment，montelukast can not only effectively improve clinical efficacy，but also can effectively reduce the incidence of adverse reactions and is worthy of clinical promotion.
, 百拇医药
Key words：Bronchial asthma；Montelukast；Clinical symptom score
支气管哮喘(asthma)是慢性炎症性呼吸科疾病，临床表现为喘息、胸闷、咳嗽及呼吸困难等，常发作于夜间与清晨，不仅严重影响患者健康，而且若治疗不及时还可造成患者死亡[1]。临床研究显示，支气管哮喘与患者免疫功能紊乱有直接关系，为此临床上常采用白三烯抑制类药物对其进行治疗，进而有效抑制气道炎症反应，调节免疫功能，改善临床症状[2]。本次我院将孟鲁司特这一新型白三烯受体拮抗剂应用到支气管哮喘临床治疗中，并取得较好临床疗效，现详述如下。
1 资料与方法
1.1 一般资料 选取天津市宁河区医院2016年1月～2017年1月收治的90例支气管哮喘患者，本次研究经过医院伦理委员会批准。依据中华医学会呼吸病学分会哮喘学组制定的《支气管哮喘防治指南(2016年版)》的诊断标准，所有患者均被确诊为支气管哮喘，并排除感染性疾病及近期应用免疫抑制剂或白三烯受体拮抗剂的患者，所有患者均签署知情同意书。以随机数表法将90例患者平均分成观察组与对照组各45例。观察组男性23例，女性22例；年龄14～75岁，平均年龄(33.01±8.14)歲。对照组男性24例，女性21例；年龄15～74岁，平均年龄(33.30±8.32)岁。两组患者一般资料对比，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(刘玉振)